48results about How to "Reduce myocardial infarction" patented technology

The invention discloses a medicinal composition for preventing and treating cardiovascular diseases, belonging to the technical field of Chinese medicines. The medicinal composition is prepared from salvianolic acids, total tanshinone and a notoginsenoside mixture in a certain weight ratio, wherein the notoginsenoside mixture is prepared by mixing ginsenoside Rb1, ginsenoside Rg1 and notoginsenoside R1; and the notoginsenoside mixture can be replaced by an equivalent amount of arasaponin. The medicinal composition has remarkable treatment effects on a coronary heart disease, angina and myocardial infarction.

The invention which belongs to the technical field of flavorings especially relates to a salt-free soy. A technical scheme of the salt-free soy comprises the following steps: 1, mixing raw materials of soybean (bean cakes and soybean meal oil cakes), wheat bran (or crushed wheat) or rice husk, moistening, and steaming them in a boiler; 2, air-cooling the raw materials, mixing the raw materials with a koji forming material, adding water, uniformly stirring them, fermenting the raw materials in a pool, and spraying oil to leach after the fermentation; and 3, heating a raw soy, adding a flavoring as needed, directly clarifying the heated raw soy if the taste needs no adjustments, sterilization-disinfecting, and packaging to form finished products after the quality detection qualification. The salt-free soy has the following beneficial effects: the oxidation resistance of the salt-free soy is 150 times higher than the oxidation resistance of vitamin C; and generations of arteriosclerosis, myocardial infarction, apoplexy, hypertension, heat diseases and cataract are reduced after the salt-free soy is taken for a long term. The salt-free soy is suitable for people needing light diets and a proper amount of salt.

A pharmaceutical composition is an organic salt formed by an organic acid rosuvastatin and an organic base azelnidipine with a molar ratio of 1:1. The pharmaceutical composition can be made into any dosage forms together with a pharmaceutically-acceptable carrier for reducing blood pressure and blood lipid, reducing myocardial infarction and treating cerebral apoplexy. The inventive pharmaceutical composition has the advantages of stable physiochemical indexes, controllable product quality, and convenient administration.

The medicine composition consists of one of ACE1, its active metabolism product and salt in treating effective amount of 0.5-100 mg, one or several kinds one B family vitamins in treating effective amount of 0.1-50 mg, and pharmaceutically acceptable carrier. The medicine composition of the present invention has the advantages of raising the treating effect of blood pressure lowering ACE1 medicine, strengthening the protecting effect of blood pressure lowering ACE1 medicine on target organ and reducing the incidence rate of hemorrhage of the ocular fundus, angina pectoris, myocardial infarction and other complications.

The health beverage capable of lowering blood viscosity is prepared with skullcap root 10-30 wt%, motherwort 20-60 wt%, selfheal 15-30 wt%, cassia seed 10-30 wt%, wild chrysanthemum flower 10-30 wt%, haw leaf 3-15 wt%, and tea 5-30 wt%. The health beverage has the health functions of inhibiting platelet aggregation, reducing packed cell volume, lowering blood viscosity, etc and thus can lower theatherosclerosis incidence rate, and prevent hypertension, myocardial infarction, etc.

The invention provides a GLP-1 small molecule compound with cardiovascular benefits, which not only can be used for treatment of diabetes mellitus, but also can be independently or jointly applied as a cardiovascular protective agent and has the pharmaceutical application of reducing cardiovascular adverse events or reducing cardiovascular adverse events in type 2 diabetes mellitus. The reduction of cardiovascular adverse events comprises reduction of the incidence rate of myocardial infarction of patients, reduction of the hospitalization frequency caused by heart failure, reduction of the risk of myocardial infarction and stroke of patients, and reduction of the cardiovascular death risk of heart failure of adults with reduced ejection fraction and the hospitalization risk caused by heart failure (NYHA II-IV level).

The invention belongs to the field of organic medicinal synthesis, and discloses C13 deuterated methyl telmisartan and a preparation method and application thereof. According to the preparation method, with C13 deuterated methanol as a C13 deuterated raw material, the C13 deuterated telmisartan is synthesized through a four-step reaction. The preparation method comprises the following steps: iodizing the C13 deuterated methanol to obtain C13 deuterated iodomethane; performing a substitution reaction on the C13 deuterated iodomethane and a compound (III) to obtain a compound (IV); performing aSuzuki coupling reaction on the compound (IV) and 2-boro methylbenzoate to obtain a compound (V); performing esterolysis on the compound (V) under an alkaline condition to obtain the C13 deuterated telmisartan. The preparation method is easy and convenient to operate; by the preparation method, a C13 deuterated reagent is saved, the cost is low and purification is easy; a purified product is obtained after rapid preparation and chromatographic purification. A standard deuterated telmisartan substance prepared by the preparation method provided by the invention is high in purity and stable in chemical properties, and can be applied to preparation of an analytical standard substance.

The invention discloses an aspirin and clopidogrel hydrogen sulfate compound preparation and a preparation method thereof, and belongs to the field of pharmaceutical preparations. The aspirin and clopidogrel hydrogen sulfate compound preparation is prepared by mixing and tabletting an aspirin enteric-coated tablet core and clopidogrel hydrogen sulfate quick-release particles. An aspirin enteric-coated tablet is composed of a drug-containing element tablet and two layers of coatings including an enteric coating and an isolation layer coating. Due to the fact that talcum powder and glyceryl monostearate are combined for use, the glyceryl monostearate has a hydrophobic effect, production of salicylic acid can be better slowed down, aspirin stability is better, and an inner isolation layer does not need to be added; and clopidogrel hydrogen sulfate granules are prepared by hot melting granulation. The aspirin and clopidogrel hydrogen sulfate compound preparation can achieve the characteristics that clopidogrel or a medicinal salt thereof can be quickly released in the stomach and the aspirin enteric-coated tablet can be released in the intestinal tract. The preparation method has the advantages of smooth production process, high production capacity, good stability and the like.

The invention relates to an antihypertensive medical composite which is composed of 0.5-100mg of angiotensin converting enzyme inhibitor with curative dose, 4-800mg of AT1 receptor antagonist, 0.1-50mg of one or more of B-complex vitamins and pharmaceutically acceptable carrier in one tablet. The invention has the advantages that the medical composite can increase the curative effect of the antihypertensive medicine, improve the target organ protection function of the medicine and reduce the incidence rate of complications such as fundus hemorrhage, angina pectoris, myocardial infarction, brain stroke, heart failure and kidney failure. In addition, the antihypertensive medical composite can be used to ensure the patient to take the medicine conveniently and reduce medical expenses.

The invention relates to a tablet composition containing enalapril and folic acid and a preparation method thereof. The tablets prepared by the preparation method are capable of effectively reducing the degradation of active ingredients of a medicine while improving the stability and safety of a compound solid preparation as well as the disintegration rate and timeliness of the medicine in the stomach and intestines; the composition meets the dosage requirements for accurate absorption, and the therapeutic effect of the medicine is remarkably improved.

The invention relates to the application of pharmaceutical composition in the process for preparing medicine to treat aspirin resistance, wherein the composition comprises (by weight ratio) Chinese angelica root 10-100mg, astragalus root 50-100mg, red peony root 10-50g, Ligusticum wallichii 20-100g, radix salvia miltiorrhiza 60-300g, cassia twig 10-100g, peach kernel 10-100g, safflower 10-100g, mulberry twigs 10-200g, achyranthes and cyathula root 10-200g, frankincense 10-150g, myrrh 10-150g, hooked uncaria 10-200g, earthworm 10-500g, buthus martensi kirsch 10-1000g, centipede 1-100 pieces, spatholobus stem 10-500g, leech 10-1000g.

The invention relates to a medicine composition containing dehydrogenated corydaline as well as a preparation method and a measurement method. The medicine composition is a composition which is mainly prepared by a method for extracting a medicinal material of corydalis tuber through the thermal refluxing of ethanol and purifying the corydalis tuber by macroporous adsorptive resin, and comprises dehydrogenated corydaline, total quaternary ammonium hydroxide, columbamine, 13-methyldehydrocorydalmine, dehydrocorybulbine and palmatine, wherein the content of the dehydrogenated corydaline, which is measured by using a high-efficiency liquid chromatography method, is not lower than 10 percent; the content of the total quaternary ammonium hydroxide in the composition, which is calculated according to the dehydrogenated corydaline, is not lower than 50 percent; and the measurement method comprises a measurement method to the dehydrogenated corydaline and a measurement method to the total quaternary ammonium hydroxide of the corydalis tuber. The medicine composition containing the dehydrogenated corydaline as well as the preparation method and the measurement method have the characteristics of simple production process, short production period, high safety, no pollution to the environment, low cost, high yield and the like, and are especially suitable for industrialized mass production; and the medicine composition containing the dehydrogenated corydaline can be used for lowering the degree of myocardial infarction and has the functions of obviously resisting myocardial ischemia and obviously prolonging the anoxia-proof time of a rat.

Several embodiments relate to methods of generating cells with therapeutic potency. Several embodiments relate to generating cells as a source of exosomes with therapeutic potency. The cells and exosomes with therapeutic potency are useful for repairing and / or regenerating damaged or diseased tissue, for example.

The invention provides an injection of aspirin and dipyridamole and its preparing process, which comprises aspirin and dipyridamole by the proportion of aspirin : dipyridamole = 1-99 : 99-1, the injection can be made into the forms of injection, freeze-dried powder injection, germ-free powder injection, and high capacity fluid infusion. The preparation can be applied for treating cardiovascular and cerebrovascular diseases.

The invention discloses a perindopril amlodipine tablet and a production process thereof. The tablet comprises the following components: perindopril tert-butylamine salt, amlodipine besylate, microcrystalline cellulose, lactose, pregelatinized starch, sodium carboxymethyl starch, magnesium stearate, silicon dioxide and talc powder. The perindopril amlodipine tablet is an effective, safe and convenient treatment medicament for hypertension patients, and has important meaning in controlling blood pressure of patients, preventing occurrence and development of heart and cerebral vessel diseases, controlling kidney diseases occurrence of hypertension patients with with diabetes, improving heart functions of the patients, and reducing occurrence rate of myocardial infarction and other serious incidents.

The invention relates to a biological capsule for treating cardiovascular and cerebrovascular diseases, which comprises rich animal collagen, nourishing powder containing rich selenium and Chinese medicinal powders, as well as glossy ganoderma spore powder and rape flowers.

The invention relates to the application of pharmaceutical composition in the process for preparing medicine to treat aspirin resistance wherein the composition comprises (by weightg ratio) Chinese angelica root 10-100mg, astragalus root 50-100mg, red peony root 10-50g, Ligusticum wallichii 20-100g, radix salvia miltiorrhiza 60-300g, cassia twig 10-100g, peach kernel 10-100g, safflower 10-100g, mulberry twigs 10-200g, achyranthes and cyathula root 10-200g, frankincense 10-150g, myrrh 10-150g, hooked uncaria 10-200g, earthworm 10-500g, buthus martensi kirsch 10-1000g, centipede 1-100 pieces, spatholobus stem 10-500g, leech 10-1000g.

The invention relates to the application of pharmaceutical composition in the process for preparing medicine to treat aspirin resistance, wherein pharmaceutical composition comprises (by weight ratio) root of red rooted saliva 50-60 parts, notoginseng 16-20 parts, borneol 0.1-3 parts, the composition can be prepared into any of the pharmacologically acceptable dose form.

The invention discloses a traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 20-30 parts of radix salviae miltiorrhizae, 15-25 parts of radix notoginseng, 15-25 parts of peach kernels, 10-20 parts of radix angelicae sinensis, 10-20 parts of flos carthami, 10-20 parts of radix astragali, 10-20 parts of radix paeoniae rubra, 5-15 parts of rhizoma chuanxiong, 5-15 parts of radix codonopsis, 5-15 parts of rhizoma polygonati and 1-10 parts of musk. The preparation method comprises the following steps: (1) weighing the raw materials; (2) respectively crushing and sieving all the raw materials, and then uniformly mixing; (3) drying; and (4) automatically and quantitatively packaging and warehousing. The product has the advantages of being small in dosage, simple and convenient to take, high in dissolution speed, good in effect, capable of being directly absorbed into blood through mucosa, capable of purifying and removing blood vessel garbage, high in availability, good in curative effect, free of gastrointestinal irritation, free of obvious toxic and side effects and the like, and has good effects of activating blood circulation to dissipate stasis, removing blood garbage and smoothing blood vessels in the heart and all over the body.

The present invention provides methods, compositions, and systems for treating a subject at risk for, with, or suspected of having, myocardial ischemia using hepatocyte secretory factors (e.g., AGP2, BMPER, FGF21, NRG4, and / or TFF3) or using factors that promote liver cell migration to ischemic myocardial tissue (e.g., IL-6 and / or MMP-2).

The invention discloses a medicine for treating fatty liver, prostatitis, diabetes mellitus, hypertension and cholesterol. The medicine is composed of multiple Chinese herbal medicines such as inonotuso bliquus pilat, Huidouba, rhodiola rosea, polygonum multiflorum, lethariella cladonioides, tall gastrodia fruits, rhodobryum giganteum par, white snow tea and gymnadenia conopsea. The medicine disclosed by the invention has the advantages that firstly the medicine can effectively treat the fatty liver, prostatitis, diabetes mellitus and hypertension when being pickled with bird eggs; secondly, the medicine can effectively treat high cholesterol, hypertension and diabetes mellitus by mixing medicine juice pickled by utilizing the bird eggs with loaches; thirdly, the medicine can effectively treat the diabetes mellitus and hypertension by mixing the medicine juice pickled by utilizing the bird eggs with eels; fourthly, the medicine can effectively treat high cholesterol, diabetes mellitus and hypertension by mixing the medicine juice pickled by utilizing the bird eggs with hairtails; and fifthly, a technical subsidiary agricultural product, namely table salt, the medicine juice with the effective ingredients pickled by duck eggs and chicken eggs as well as the loaches or eels and hairtails are mixed, so that a combination drug is obtained. The combination drug can protect liver and kidney, a patient can eat the combination drug as vegetables at meal, economic burden of the patient is reduced, and everyone loves to eat the combination drug; both prevention and treatment can be realized; and the combination drug is a green health product.

The invention discloses fruit wine for preventing cardiovascular diseases prepared via a special method. The fruit wine is prepared by: crushing, by weight, 50-60 parts of fresh lemon fruit, 40-50 parts of raisin tree fruit and 5-20 parts of rose flower, stirring for homogenizing, adding an enzyme, and enzymatically hydrolyzing by warm bath at 37 DEG C; filtering to obtain enzymatic hydrolytic filtrates, combining the enzymatic hydrolytic filtrates, and adjusting pH to 3-5 to obtain mixed fruit juice at sugar degree of 16-20%; sterilizing the mixed fruit juice, adding Rhizopus, aroma-producing yeast, activated dry yeast and lactic acid bacteria, and fermenting for 15-20 days to obtain fermentation broth; adding an enzyme to the fermentation broth, enzymatically hydrolyzing again, filtering, and ageing the filtrate to obtain the target fruit wine. The fruit wine has unique flavor, can lower blood lipid, and can well change blood viscosity and prevent cardiovascular diseases; compared with Baijiu or common fruit wine having the same alcohol by volume, the fruit wine allows ethanol and acetaldehyde in the body to be cleared efficiently and quickly after being drunk, can cause very little harm to the liver, and may be drunk often as functional fruit wine to prevent cardiovascular diseases.

The invention belongs to the field of organic and pharmaceutical synthesis, and discloses deuterated methyl telmisartan as well as a preparation method and application thereof. The method adopts 3-methyl-4-nitrobenzoic acid as a raw material, adopts deuterated iodomethane as a deuterated raw material and synthesizes deuterated telmisartan-d3 by virtue of eleven-step reaction. The preparation method is simple in operation, saves a deuterated reagent, is low in cost and easy to purify. After being rapidly purified by preparation chromatography, a pure product is obtained. A deuterated telmisartan standard product prepared according to the invention is high in purity and stable in chemical performance; and the preparation of the standard product can be conveniently analyzed. The preparation method can be used for producing and analyzing a deuterated internal standard substance used when the deuterated telmisartan is detected; and a medicinal composition can be prepared, i.e, the medicinalcomposition can be used for angiotensin II receptor antagonist to lower the blood pressure and can lower the blood pressure of patients with high cardiovascular disease risk and diabetic patients.

The invention relates to the application of telaprevir in the preparation of drugs for treating ischemia / reperfusion injury and cell protection drugs. Telaprevir is used to prepare the medicine for the treatment of ischemia / reperfusion injury, especially the medicine for the treatment of cardiomyocyte and nerve cell injury, this medicine especially has good protective effect to the heart, cerebral ischemia / reperfusion (myocardium Infarction, ischemic stroke), can significantly reduce cardiac and cerebral ischemia / reperfusion injury.

The invention relates to an application of a pharmaceutical composition containing angiotensin converting enzyme inhibitor (ACEI) and B vitamins in preparing a medicine for treating peripheral artery diseases. The pharmaceutical composition of the invention not only can treat the peripheral artery diseases, but also has a curative effect on hypertension caused by the peripheral artery diseases, simultaneously enhances the protective action of the angiotensin converting enzyme inhibitor on target organs, and reduces the incidence of complications such as myocardial infarction, cerebral apoplexy, heart failure, kidney failure, and the like.

The invention discloses the use of yam total saponin in the process for preparing anti-aspirin resisting medicine, wherein the preparation comprises water extraction, enzymolysis method or supercritical extraction method. calculated by dried article, the content of steroid glycoside is greater than 35%.

The medicine composition consists of one of AT1 receptor antagonist, its active metabolism product, ester and salt in treating effective amount of 4-800 mg, one or several kinds one B family vitamins in treating effective amount of 0.1-50 mg, and pharmaceutically acceptable carrier. The medicine composition of the present invention has the beneficial effects of raising the treating effect of blood pressure lowering AT1 receptor antagonist, strengthening the protecting effect of blood pressure lowering AT1 receptor antagonist on target organ and reducing the incidence rate of hemorrhage of the ocular fundus, angina pectoris, myocardial infarction and other complications.

The invention relates to the application of pharmaceutical composition in the process for preparing medicine to treat aspirin resistance, wherein the pharmaceutical composition comprises (by weight ratio) corydalis tuber 100-2000 weight units, Siphonostegia chinensis Benth 150-1800 weight units, drynaria 200-2500 weight units, gen-seng 50-1000 weight units.